Seven-Signal Proteomic Signature for Detection of Operable Pancreatic Ductal Adenocarcinoma and Their Discrimination from Autoimmune Pancreatitis

There is urgent need for biomarkers that provide early detection of pancreatic ductal adenocarcinoma (PDAC) as well as discrimination of autoimmune pancreatitis, as current clinical approaches are not suitably accurate for precise diagnosis. We used mass spectrometry to analyze protein profiles of m...

Full description

Bibliographic Details
Main Authors:	Yanagisawa, Kiyoshi, Tomida, Shuta, Matsuo, Keitaro, Arima, Chinatsu, Kusumegi, Miyoko, Yokoyama, Yukihiro, Ko, Shigeru B. H., Mizuno, Nobumasa, Kawahara, Takeo, Kuroyanagi, Yoko, Takeuchi, Toshiyuki, Goto, Hidemi, Yamao, Kenji, Nagino, Masato, Tajima, Kazuo, Takahashi, Takashi
Format:	Online
Language:	English
Published:	Hindawi Publishing Corporation 2012
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3361197/

id	pubmed-3361197
recordtype	oai_dc
spelling	pubmed-33611972012-06-06 Seven-Signal Proteomic Signature for Detection of Operable Pancreatic Ductal Adenocarcinoma and Their Discrimination from Autoimmune Pancreatitis Yanagisawa, Kiyoshi Tomida, Shuta Matsuo, Keitaro Arima, Chinatsu Kusumegi, Miyoko Yokoyama, Yukihiro Ko, Shigeru B. H. Mizuno, Nobumasa Kawahara, Takeo Kuroyanagi, Yoko Takeuchi, Toshiyuki Goto, Hidemi Yamao, Kenji Nagino, Masato Tajima, Kazuo Takahashi, Takashi Research Article There is urgent need for biomarkers that provide early detection of pancreatic ductal adenocarcinoma (PDAC) as well as discrimination of autoimmune pancreatitis, as current clinical approaches are not suitably accurate for precise diagnosis. We used mass spectrometry to analyze protein profiles of more than 300 plasma specimens obtained from PDAC, noncancerous pancreatic diseases including autoimmune pancreatitis patients and healthy subjects. We obtained 1063 proteomic signals from 160 plasma samples in the training cohort. A proteomic signature consisting of 7 mass spectrometry signals was used for construction of a proteomic model for detection of PDAC patients. Using the test cohort, we confirmed that this proteomic model had discrimination power equal to that observed with the training cohort. The overall sensitivity and specificity for detection of cancer patients were 82.6% and 90.9%, respectively. Notably, 62.5% of the stage I and II cases were detected by our proteomic model. We also found that 100% of autoimmune pancreatitis patients were correctly assigned as noncancerous individuals. In the present paper, we developed a proteomic model that was shown able to detect early-stage PDAC patients. In addition, our model appeared capable of discriminating patients with autoimmune pancreatitis from those with PDAC. Hindawi Publishing Corporation 2012 2012-05-14 /pmc/articles/PMC3361197/ /pubmed/22675630 http://dx.doi.org/10.1155/2012/510397 Text en Copyright © 2012 Kiyoshi Yanagisawa et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Yanagisawa, Kiyoshi Tomida, Shuta Matsuo, Keitaro Arima, Chinatsu Kusumegi, Miyoko Yokoyama, Yukihiro Ko, Shigeru B. H. Mizuno, Nobumasa Kawahara, Takeo Kuroyanagi, Yoko Takeuchi, Toshiyuki Goto, Hidemi Yamao, Kenji Nagino, Masato Tajima, Kazuo Takahashi, Takashi
spellingShingle	Yanagisawa, Kiyoshi Tomida, Shuta Matsuo, Keitaro Arima, Chinatsu Kusumegi, Miyoko Yokoyama, Yukihiro Ko, Shigeru B. H. Mizuno, Nobumasa Kawahara, Takeo Kuroyanagi, Yoko Takeuchi, Toshiyuki Goto, Hidemi Yamao, Kenji Nagino, Masato Tajima, Kazuo Takahashi, Takashi Seven-Signal Proteomic Signature for Detection of Operable Pancreatic Ductal Adenocarcinoma and Their Discrimination from Autoimmune Pancreatitis
author_facet	Yanagisawa, Kiyoshi Tomida, Shuta Matsuo, Keitaro Arima, Chinatsu Kusumegi, Miyoko Yokoyama, Yukihiro Ko, Shigeru B. H. Mizuno, Nobumasa Kawahara, Takeo Kuroyanagi, Yoko Takeuchi, Toshiyuki Goto, Hidemi Yamao, Kenji Nagino, Masato Tajima, Kazuo Takahashi, Takashi
author_sort	Yanagisawa, Kiyoshi
title	Seven-Signal Proteomic Signature for Detection of Operable Pancreatic Ductal Adenocarcinoma and Their Discrimination from Autoimmune Pancreatitis
title_short	Seven-Signal Proteomic Signature for Detection of Operable Pancreatic Ductal Adenocarcinoma and Their Discrimination from Autoimmune Pancreatitis
title_full	Seven-Signal Proteomic Signature for Detection of Operable Pancreatic Ductal Adenocarcinoma and Their Discrimination from Autoimmune Pancreatitis
title_fullStr	Seven-Signal Proteomic Signature for Detection of Operable Pancreatic Ductal Adenocarcinoma and Their Discrimination from Autoimmune Pancreatitis
title_full_unstemmed	Seven-Signal Proteomic Signature for Detection of Operable Pancreatic Ductal Adenocarcinoma and Their Discrimination from Autoimmune Pancreatitis
title_sort	seven-signal proteomic signature for detection of operable pancreatic ductal adenocarcinoma and their discrimination from autoimmune pancreatitis
description	There is urgent need for biomarkers that provide early detection of pancreatic ductal adenocarcinoma (PDAC) as well as discrimination of autoimmune pancreatitis, as current clinical approaches are not suitably accurate for precise diagnosis. We used mass spectrometry to analyze protein profiles of more than 300 plasma specimens obtained from PDAC, noncancerous pancreatic diseases including autoimmune pancreatitis patients and healthy subjects. We obtained 1063 proteomic signals from 160 plasma samples in the training cohort. A proteomic signature consisting of 7 mass spectrometry signals was used for construction of a proteomic model for detection of PDAC patients. Using the test cohort, we confirmed that this proteomic model had discrimination power equal to that observed with the training cohort. The overall sensitivity and specificity for detection of cancer patients were 82.6% and 90.9%, respectively. Notably, 62.5% of the stage I and II cases were detected by our proteomic model. We also found that 100% of autoimmune pancreatitis patients were correctly assigned as noncancerous individuals. In the present paper, we developed a proteomic model that was shown able to detect early-stage PDAC patients. In addition, our model appeared capable of discriminating patients with autoimmune pancreatitis from those with PDAC.
publisher	Hindawi Publishing Corporation
publishDate	2012
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3361197/
_version_	1611532733613342720

Seven-Signal Proteomic Signature for Detection of Operable Pancreatic Ductal Adenocarcinoma and Their Discrimination from Autoimmune Pancreatitis

Similar Items